Severe acute respiratory syndrome coronavirus

Open Orphan plc Announces £3m COVID-19 Challenge Virus Manufacturing Contract

Retrieved on: 
Monday, May 10, 2021
Research, Infectious diseases, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Coronavirus, COVID-19

These challenge agents are then used in controlled human infection studies, an area that hVIVO has focussed on since 2001.\nOpen Orphan has successfully initiated the development of a number of Coronavirus challenge viruses.

Key Points: 
  • These challenge agents are then used in controlled human infection studies, an area that hVIVO has focussed on since 2001.\nOpen Orphan has successfully initiated the development of a number of Coronavirus challenge viruses.
  • The Company has already developed the initial circulating COVID-19 (SARS-CoV-2) virus as part of the Human Challenge Programme in partnership with the UK Government.\nCathal Friel, Executive Chairman of Open Orphan plc commented: \xe2\x80\x9cThis contract is a great example of how our unique abilities to provide an all encompassing solution for human challenge trials sets us apart.
  • Production of a SARS-CoV-2 variant challenge virus builds upon our knowledge and learnings from manufacturing and characterising the original Wuhan-like D614G SARS-CoV-2 virus.
  • Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD.

Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose

Retrieved on: 
Monday, May 10, 2021
Coronaviridae, Biotechnology, Vaccination, Severe acute respiratory syndrome coronavirus, Vaccines, Life sciences, Articles, COVID-19 vaccines

In this study, a single intranasal dose of AdCOVID provided sterilizing immunity in the lungs of vaccinated mice, in contrast to the development of dense pulmonary infection and disease in the lungs of non-vaccinated mice following infection with SARS-CoV-2.

Key Points: 
  • In this study, a single intranasal dose of AdCOVID provided sterilizing immunity in the lungs of vaccinated mice, in contrast to the development of dense pulmonary infection and disease in the lungs of non-vaccinated mice following infection with SARS-CoV-2.
  • AdCOVID is a novel, single-dose intranasal vaccine candidate for COVID-19.\n\xe2\x80\x9cThese latest data are very exciting, as they confirm and expand upon the numerous potential advantages of our differentiated intranasal vaccine approach,\xe2\x80\x9d said Scot Roberts, Ph.D., Chief Scientific Officer at Altimmune.
  • \xe2\x80\x9cIn the current study, we found a heavy burden of infectious SARS-CoV-2 virus in the lungs of non-vaccinated mice following challenge with the virus.
  • Roberts continued, \xe2\x80\x9cThese data suggest that a single intranasal vaccination with AdCOVID may provide sterilizing immunity that neutralizes infectious virus, which is believed to be the best way to block viral transmission.

Global PCR (qPCR, dPCR, Singleplex & Multiplex) Markets Report 2021-2025 with Updated Impacts of COVID-19 Diagnostics - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Genetics, Pharmaceutical, Health, Sarbecovirus, Zoonoses, Animal diseases, Infectious diseases, Severe acute respiratory syndrome coronavirus, Lung cancer, Severe acute respiratory syndrome, Quidel Corporation

b"Quidel Expects SARS-CoV-2 Testing Demand to Continue 'Through 2022, and Beyond'\nIsrael's Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays\n"

Key Points: 

b"Quidel Expects SARS-CoV-2 Testing Demand to Continue 'Through 2022, and Beyond'\nIsrael's Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays\n"

GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 6, 2021
Zoonoses, Sarbecovirus, Animal diseases, Veterinary medicine, Bat virome, Merbecovirus, Betacoronavirus, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, COVID-19

Details are provided further below.\nCapital Resources\xe2\x80\x93 On February 11, 2021, GeoVax supplemented its cash resources through a $10.3 million follow-on offering of common stock ($9.4 million net proceeds).

Key Points: 
  • Details are provided further below.\nCapital Resources\xe2\x80\x93 On February 11, 2021, GeoVax supplemented its cash resources through a $10.3 million follow-on offering of common stock ($9.4 million net proceeds).
  • SARS-CoV-2 is a type of coronavirus (a Betacoronavirus) that also causes Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
  • We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.
  • We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.\n'

Aditxt Signs Channel Partner Agreement with Meridian HSN to Make AditxtScore™ for COVID-19 Available to its Network of Healthcare Provider Partners

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Immunology, Branches of biology, Antibodies, Glycoproteins, Clinical medicine, Neutralizing antibody, Severe acute respiratory syndrome coronavirus

AditxtScore applications include the recently commercialized AditxtScore for COVID-19, developed for use in detecting antibodies and neutralizing antibodies against SARS-CoV-2 antigens.

Key Points: 
  • AditxtScore applications include the recently commercialized AditxtScore for COVID-19, developed for use in detecting antibodies and neutralizing antibodies against SARS-CoV-2 antigens.
  • "Key stakeholders will need to adapt to emerging data and new variants both in the US and around the world, and the AditxtScore platform potentially represents an important complement.
  • We are thrilled to add Meridian HSN to our growing AditxtScore Channel Partner network with an opportunity to support its clients, including national hotel chains, aviation and hospital networks.
  • Generalized population levels that track the total number vaccinated may not provide an accurate safeguard against the spread of the virus.

Dell Technologies and i2b2 tranSMART Foundation Create "Digital Twins" to Treat Long-Haul COVID-19

Retrieved on: 
Wednesday, May 5, 2021
Sarbecovirus, Respiratory diseases, COVID-19, Zoonoses, Long Covid, Animal diseases, PASC, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Simulation

"Working together with the i2b2tranSMART Foundation,we will apply ourexpertiseand technologyto build digital twins, share data, conduct simulations and analyses using these insights to helpunderstand and better treat patients with long-haul COVID.

Key Points: 
  • "Working together with the i2b2tranSMART Foundation,we will apply ourexpertiseand technologyto build digital twins, share data, conduct simulations and analyses using these insights to helpunderstand and better treat patients with long-haul COVID.
  • So-called long haulers suffer from what is known formally as Post-Acute Sequelae of SARS-CoV-2 (PASC).
  • "This new AI-driven platform will help them use the explosion of research findings to deliver better care and precision treatments for their patients.
  • By creating these digital twins, we are taking clinical research to a whole new level.

Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

Retrieved on: 
Wednesday, May 5, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Coronaviridae, Medicine, Sarbecovirus, COVID-19 vaccines, Clinical trials, COVID-19, Public health, Zoonoses, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Neutralizing antibody, ADG20, Adagio Therapeutics, ADG20, ADAGIO THERAPEUTICS

Trial initiation is supported bypositive preliminary data from the company\xe2\x80\x99s ongoing Phase 1 trial in healthy volunteers.

Key Points: 
  • Trial initiation is supported bypositive preliminary data from the company\xe2\x80\x99s ongoing Phase 1 trial in healthy volunteers.
  • The Phase 1 trial was designed to evaluate the safety, tolerability, pharmacokinetics and serum SARS-CoV-2 neutralizing antibody levels of various ADG20 dose regimens.
  • Adagio is advancing ADG20 through multiple clinical trials on a global basis.\nAdagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV and additional pre-emergent coronaviruses.
  • Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.

eFFECTOR and Quantitative Biosciences Institute (QBI) at UCSF Receive $5.0 Million from DARPA to Evaluate Zotatifin in COVID-19

Retrieved on: 
Tuesday, May 4, 2021
Branches of biology, Sarbecovirus, Biochemistry, Biology, Gene expression, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Eukaryotic initiation factor 4F

The agreement is a subaward of a DARPA research program awarded to the Quantitative Biosciences Institute (QBI) at University of California, San Francisco (UCSF), headed by Brian Shoichet, Ph.D., professor, department of pharmaceutical chemistry, to identify agents active against SARS-CoV-2 infections.

Key Points: 
  • The agreement is a subaward of a DARPA research program awarded to the Quantitative Biosciences Institute (QBI) at University of California, San Francisco (UCSF), headed by Brian Shoichet, Ph.D., professor, department of pharmaceutical chemistry, to identify agents active against SARS-CoV-2 infections.
  • SARS-CoV-2 is an RNA virus that hijacks the human cellular machinery\xe2\x80\x94including eIF4A\xe2\x80\x94to replicate.
  • Since zotatifin inhibits the translation of mRNA in the non-coding region of mRNAs, it is not limited to any KRAS activating mutation subtypes.
  • Learn more at https://www.ucsf.edu .\nThe information stated above was prepared by eFFECTOR and reflects solely the opinion of the corporation.

Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs

Retrieved on: 
Monday, May 3, 2021
Sarbecovirus, Zoonoses, Bat virome, Medical specialties, Virology, Antiviral drugs, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome–related coronavirus, Coronavirus, 3C-like protease

\xe2\x80\x9cThese drug candidates bind to a highly conserved region of the active site of SARS-CoV-2 protease that is required for SARS-CoV-2 viral replication.

Key Points: 
  • \xe2\x80\x9cThese drug candidates bind to a highly conserved region of the active site of SARS-CoV-2 protease that is required for SARS-CoV-2 viral replication.
  • Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-2 infected mice.
  • In addition to these two SARS-CoV-2 protease programs, we are also developing novel SARS-CoV-2 inhibitors that block viral replication and transcription.
  • Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

Taconic Biosciences Launches New COVID-19 Mouse Model

Retrieved on: 
Thursday, April 29, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Animal diseases, Variants of SARS-CoV-2, Taconic Biosciences, Angiotensin-converting enzyme 2, Severe acute respiratory syndrome coronavirus, COVID-19, Severe acute respiratory syndrome

b"RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model.

Key Points: 
  • b"RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model.
  • This human ACE2 (hACE2) transgenic mouse expands Taconic\xe2\x80\x99s COVID-19 research toolkit.\nIn October 2020, Taconic launched its first hACE2 model .
  • The AC70 mouse experiences a lethal response to infection by SARS-CoV-2, the virus that causes COVID-19.
  • Conversely, the new AC22 mouse is lethality-resistant, enabling therapeutic, vaccine, and post-infection symptom research.\nAlthough various hACE2 mouse models of lethal SARS-CoV-2 infection exist, the hACE2 AC22 lethality-resistant model is important because it permits study of sublethal infection.